Natera
Open
$211.78
Prev. Close
$212.10
High
$212.28
Low
$211.48
Market Snapshot
$30.06B
-132.8
-1.53
$1.7B
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 6,135 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. The company is headquartered in Austin, Texas and currently employs 6,135 full-time employees. The company went IPO on 2015-07-02. The firm's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. The company has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Recently from Cashu
Natera Partners with CytoDyn to Transform Personalized Cancer Care and Treatment Effectiveness
Natera (Ticker: NTRA) is making strides in oncology with a new partnership aimed at revolutionizing personalized cancer care. The company, recognized for its advancements in genetic testing, has recen…
Natera Enhances Panorama Test, Reducing No-Call Rate to 0.5% for Prenatal Screening
Natera (Ticker: NTRA) recently announces crucial advancements in its Panorama non-invasive prenatal test, addressing significant challenges in fetal fraction sampling. The latest enhancement of the Pa…
Natera Showcases Prospera Platform Advancements at ISHLT Meeting for Transplant Diagnostics
Natera, Inc., a pioneer in genetic testing, enhances its presence in transplant diagnostics at the recent International Society for Heart and Lung Transplantation (ISHLT) meeting. The company showcase…
Natera Reveals Key Prospera Test Findings at ISHLT Annual Meeting, Impacting Shareholder Confidence
Natera, Inc. showcases groundbreaking clinical findings for its Prospera transplant test at the 2026 ISHLT Annual Meeting, marking a significant milestone in the realm of transplant monitoring. These…